Suicidal risk during controlled clinical investigations of fluvoxamine

Journal of Clinical Psychiatry

Volumn 57, Issue 9, 1996, Pages 415-421

  Letizia, Cynthia ^a   Kapik, Barry ^b   Flanders, W Dana ^c  

^a Solvay Pharmaceuticals Inc   (Netherlands)

^b CIBA Vision Corporation   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SUICIDAL BEHAVIOR; SUICIDE;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SUICIDE; SUICIDE, ATTEMPTED;

EID: 0029760695     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Fawcett J, Scheftner WA, Fogg L, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990;147:1189-1194
2. Guze SB, Robins E. Suicide and primary affective disorders. Br J Psychiatry 1970;117:437-438
3. Moscicki EK, O'Carroll P, Rae DS, et al. Suicide attempts in the Epidemiolgic Catchment Area study. Yale J Biol Med 1988;61: 259-268
4. Petronis KR, Samuels JF, Moscicki EK, et al. An epidemiolgic investigation of potential risk factors for suicide attempts. Soc Psychiatry Psychiatr Epidemiol 1990;25:193-199
5. Damluji NF, Ferguson JM. Paradoxical worsening of depressive symptomatology caused by antidepressants. J Clin Psychopharmacol 1988;8: 347-349
6. Fawcett J. The morbidity and mortality of clinical depression. Int Clin Psychopharmacol 1993;8:217-220
7. Pokorny AD. Prediction of suicide in psychiatric patients. Arch Gen Psychiatry 1983;40:249-257
8. Henry JA. Toxicity of antidepressants: comparison with fluoxetine. Int Clin Psychopharmacol 1992;6(suppl 6):22-27
9. Banki CM. A trial of fluvoxamine in suicidal patients: prophylactic potential? In: Montgomery SA, Goeting NM, eds. Current Approaches: Suicide and Attempted Suicide Risk Factors, Management and Prevention. Southhampton, UK: Ashford Colour Press; 1991
10. Henry JA. Overdose and safety with fluvoxamine. Int Clin Psychopharmacol 1991;6(suppl 3):41-47
11. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ 1995;310:221-224
12. Kapur S, Mieczkowski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 1992;268:3441-3445
13. Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992;53(2, suppl):61-66
14. Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 1991;52: 491-493
15. Bost RO, Kemp PM. A possible association between fluoxetine use and suicide. J Anal Toxicol 1992;16:142-145
16. Morton WA, Lydiard RB. Fluoxetine-associated side effects and suicidality [letter]. J Clin Psychopharmacol 1993;13(4):292-295
17. Teicher MH, Glod CA, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990;147:207-210
18. Hamilton MS, Opler LA. Akathisia, suicidality and fluoxetine. J Clin Psychiatry 1992;53:401-406
19. Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf 1993;8:186-212
20. Hamilton A. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
21. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985;41:55-68
22. Sato T. Confidence intervals for effect parameters common in cancer epidemiology. Environ Health Perspect 1990;37:95-101
23. StatXact User Manual. Cambridge, Mass: Cytel Software; 1989
24. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiological Research: Principles and Quantitative Methods. New York, NY: Van Nostrand Reinhold; 1982
25. SAS Institute Inc. SAS User's Guide: Statistics. 5th ed. Cary, NC: SAS Institute; 1985
26. Beasley CM, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicidality: absence of association in controlled depression trials. BMJ 1991;303: 685-692
27. Mewett S. Suicidal thoughts and behavior with paroxetine [abstract]. In: New Research Program and Abstracts of the 144th Annual Meeting of the American Psychiatric Association; May 11-16, 1991; New Orleans, La. NR647:203
28. López-Ibor JJ Jr. Reduced suicidality with paroxetine. European Psychiatry 1993;8(suppl 1):17s-19s
29. Wagner W, Zaborny BA, Gray TE. Fluvoxamine: a review of its safety profile in world-wide studies. Int Clin Psychopharmacol 1994;9:223-227
30. Edwards JG, Inman HW, Wilton L, et al. Prescription-event monitoring of 10 401 patients treated with fluvoxamine. Br J Psychiatry 1994;164: 387-395
31. Committee on Safety of Medicines. Focus: safety of fluoxetine (Prozac): comparison with fluvoxamine (Faverin). Current Contents June 1992, No. 34. Committee on Safety of Medicines, London, UK
32. Feighner JP, Robins E, Guze SB, et al. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry 1972;26:57-62